Breakthrough serum triage technology using artificial intelligence for early detection

of brain cancer and other diseases

ClinSpec Dx™ are pioneering a new spectroscopic method for blood serum analysis, allowing same-day detection and grading of a range of diseases, with first applications to brain cancer.

Taking on brain cancer

38% of patients have to visit their GP more than five times before being diagnosed with brain cancer. 62% are only diagnosed in an emergency. This is why brain cancer reduces life expectancy more than any other cancer.

ClinSpec Dx™ aims to change these statistics.

Leading medical and industry partners

Under development at University of Strathclyde, Scotland, ClinSpec Dx™ has won multiple awards, received high-growth spinout funding from Scottish Enterprise and is working with leading medical suppliers, distributors, hospitals, laboratories and clinics worldwide. 

Available soon

With proof-of-concept and commercial / health viability tests complete, ClinSpec Dx is currently undergoing diagnostic accuracy studies at Western General Hospital, Edinburgh, with an anticipated roadmap to commercial launch in 2021.

ClinSpec Dx will spin out from University of Strathclyde in Q3 2018, with full worldwide licensing of all patents and technology.

Newsroom

ClinSpec DX has won multiple awards, received high-growth spinout funding from Scottish Enterprise and been featured by BBC News and other press outlets.

Read our latest updates, view our videos, follow us or download our media kit here. 

Investors

ClinSpec Dx serves the fast growing in vitro cancer diagnostics market.

With a compelling, patent-pending solution with wide ranging application, we are seeking equity investors, mentors and industry partners with experience in international counter diagnostics supply and scale, particularly in the USA.